Ownership and insider activity for Pharvaris N.V. (PHVS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Price
| Price | $38.50 |
| Market Cap | $2.7B |
| Exchange | NASDAQ |
| Country | CH |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-14 | Souverijns Wim | M-Exempt | 20,000 | $349K |
| 2026-09-14 | Souverijns Wim | M-Exempt | 20,000 | $349K |
| 2026-09-14 | Souverijns Wim | S-Sale | 20,000 | $786K |
| 2026-09-15 | Souverijns Wim | S-Sale | 6,090 | $237K |
| 2026-09-11 | Lu Peng | M-Exempt | 15,000 | $39K |
| 2026-09-11 | Lu Peng | S-Sale | 15,000 | $602K |
| 2026-09-11 | Lu Peng | F-InKind | 109 | $4K |
| 2026-09-14 | Lu Peng | F-InKind | 117 | $4K |
| 2026-09-14 | Modig Berndt | S-Sale | 2,291 | $90K |
| 2026-09-10 | Lesage Anne | M-Exempt | 30,000 | $242K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.8M | $5.4M | $20.3M | $98.6M | $209.4M | $161.8M | $391.2M | $280.7M | $291.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1056 | 0 | $210843 | $569578 | $700079 | $382468 | $1.0M | $2.9M | $4.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $4.0M | 0 | 0 | 0 |
| Total Current Assets | $4.8M | $5.4M | $20.6M | $101.0M | $211.6M | $166.8M | $397.9M | $289.4M | $299.2M |
| Property, Plant & Equipment | 0 | 0 | $12927 | $48503 | $351349 | $626439 | $455571 | $1.5M | $1.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.8M | $5.4M | $20.6M | $101.1M | $212.1M | $167.7M | $398.7M | $291.4M | $301.5M |
| Accounts Payable | $60472 | $246356 | $517771 | $656448 | $2.1M | $6.0M | $2.9M | $4.6M | $5.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $138836 | $481340 | $1.9M | $5.3M | $7.0M | $18.2M | $14.6M | $23.0M | $29.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $138836 | $481340 | $1.9M | $5.3M | $7.1M | $18.5M | $14.6M | $23.6M | $30.2M |
| Retained Earnings | -$6.1M | -$10.4M | -$18.5M | -$44.5M | -$87.6M | -$164.2M | -$265.9M | -$402.3M | -$579.6M |
| Total Equity | $4.7M | $5.0M | $18.7M | $95.8M | $205.0M | $149.3M | $384.0M | $267.8M | $271.3M |
| Total Debt | 0 | 0 | 0 | 0 | $250184 | $436822 | $238905 | $861470 | $776798 |
| Net Debt | -$4.8M | -$5.4M | -$20.3M | -$98.6M | -$209.1M | -$161.4M | -$391.0M | -$279.9M | -$290.9M |
| Working Capital | $4.7M | $5.0M | $18.7M | $95.6M | $204.6M | $148.6M | $383.2M | $266.4M | $269.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 24.30 |
Profitability
| Return on Equity | -61.24% |
| Return on Invested Capital | -60.72% |
| Return on Assets | -52.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARDX · BCRX · IMNM · MAZE · NTLA · ORIC · SYRE
Explore sector: Healthcare · Biotechnology
More sections of PHVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks